000129659 001__ 129659
000129659 005__ 20240731103327.0
000129659 0247_ $$2doi$$a10.3390/scipharm91040051
000129659 0248_ $$2sideral$$a135873
000129659 037__ $$aART-2023-135873
000129659 041__ $$aeng
000129659 100__ $$aAlonso Llorente, Alba
000129659 245__ $$aThe correlation of two different real-time PCR devices for the analysis of CYP2C19 pharmacogenetic results
000129659 260__ $$c2023
000129659 5060_ $$aAccess copy available to the general public$$fUnrestricted
000129659 5203_ $$aCYP2C19 is a highly polymorphic gene responsible for the metabolism of commonly used drugs. CYP2C19*1, the wild-type allele, is associated with normal enzyme activity, whereas CYP2C19*2 and CYP2C19*17 lead to null and increased enzyme activity, respectively. The use of different instruments to perform the same pharmacogenetic tests should not affect the reliability of the results reported to clinicians, as required by the ISO 15189 standard. Genotyping assays allowed for the identification of gene variants corresponding to the CYP2C19*2 and CYP2C19*17 haplotypes in 44 selected samples. Each sample was analyzed in duplicate using the Thermo Fisher Taqman Drug Metabolism probes CYP2C19*2: c_25986767_70 (rs4244285) and CYP2C19*17: c_469857_10 (rs12248560). The experiments were performed on two widely used types of real-time PCR analyzers: ABI PRSIM™7500 and QuantStudioTM12KFlex (both from Applied Biosystems, Thermofisher). The data were analyzed in a Thermo Fisher Cloud facility. The analysis was performed independently by two qualified professionals. Both different instruments and analysts’ interpretations were consistent in identifying the native homozygous, heterozygous, and mutant homozygous variants for CYP2C19*2 and CYP2C19*17. The results provided by both the primary and backup analyzers showed a perfect correlation. This would allow for the use of the backup analyzer in case the main one is not available.
000129659 540__ $$9info:eu-repo/semantics/openAccess$$aby$$uhttp://creativecommons.org/licenses/by/3.0/es/
000129659 592__ $$a0.412$$b2023
000129659 593__ $$aPharmaceutical Science$$c2023$$dQ2
000129659 594__ $$a4.6$$b2023
000129659 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/publishedVersion
000129659 700__ $$aSalgado Garrido, Josefa
000129659 700__ $$aTeijido Hermida, Oscar
000129659 700__ $$aGonzález Andrade, Fabricio
000129659 700__ $$aValiente Martín, Alberto
000129659 700__ $$0(orcid)0000-0001-8064-8138$$aFanlo Villacampa, Ana$$uUniversidad de Zaragoza
000129659 700__ $$0(orcid)0000-0003-4629-6743$$aVicente Romero, Jorge$$uUniversidad de Zaragoza
000129659 7102_ $$11012$$2315$$aUniversidad de Zaragoza$$bDpto. Farmac.Fisiol.y Med.L.F.$$cÁrea Farmacología
000129659 773__ $$g91, 4 (2023), 51 [7 pp.]$$tScientia Pharmaceutica$$x0036-8709
000129659 8564_ $$s502227$$uhttps://zaguan.unizar.es/record/129659/files/texto_completo.pdf$$yVersión publicada
000129659 8564_ $$s2759294$$uhttps://zaguan.unizar.es/record/129659/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada
000129659 909CO $$ooai:zaguan.unizar.es:129659$$particulos$$pdriver
000129659 951__ $$a2024-07-31-09:45:10
000129659 980__ $$aARTICLE